Cargando…

The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature

Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%–10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kacar, Mark, Savic, Sinisa, van der Hilst, Jeroen C H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069573/
https://www.ncbi.nlm.nih.gov/pubmed/32210604
http://dx.doi.org/10.2147/JIR.S206204
_version_ 1783505803521556480
author Kacar, Mark
Savic, Sinisa
van der Hilst, Jeroen C H
author_facet Kacar, Mark
Savic, Sinisa
van der Hilst, Jeroen C H
author_sort Kacar, Mark
collection PubMed
description Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%–10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1β, has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment.
format Online
Article
Text
id pubmed-7069573
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70695732020-03-24 The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature Kacar, Mark Savic, Sinisa van der Hilst, Jeroen C H J Inflamm Res Review Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%–10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1β, has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment. Dove 2020-03-09 /pmc/articles/PMC7069573/ /pubmed/32210604 http://dx.doi.org/10.2147/JIR.S206204 Text en © 2020 Kacar et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Kacar, Mark
Savic, Sinisa
van der Hilst, Jeroen C H
The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
title The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
title_full The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
title_fullStr The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
title_full_unstemmed The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
title_short The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
title_sort efficacy, safety and tolerability of canakinumab in the treatment of familial mediterranean fever: a systematic review of the literature
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069573/
https://www.ncbi.nlm.nih.gov/pubmed/32210604
http://dx.doi.org/10.2147/JIR.S206204
work_keys_str_mv AT kacarmark theefficacysafetyandtolerabilityofcanakinumabinthetreatmentoffamilialmediterraneanfeverasystematicreviewoftheliterature
AT savicsinisa theefficacysafetyandtolerabilityofcanakinumabinthetreatmentoffamilialmediterraneanfeverasystematicreviewoftheliterature
AT vanderhilstjeroench theefficacysafetyandtolerabilityofcanakinumabinthetreatmentoffamilialmediterraneanfeverasystematicreviewoftheliterature
AT kacarmark efficacysafetyandtolerabilityofcanakinumabinthetreatmentoffamilialmediterraneanfeverasystematicreviewoftheliterature
AT savicsinisa efficacysafetyandtolerabilityofcanakinumabinthetreatmentoffamilialmediterraneanfeverasystematicreviewoftheliterature
AT vanderhilstjeroench efficacysafetyandtolerabilityofcanakinumabinthetreatmentoffamilialmediterraneanfeverasystematicreviewoftheliterature